It’s like surgically inserting a permanent contact lens. The EVO ICL procedure is being done at Eye Surgeons Associates as an alternative for patients who don’t qualify for LASIK due to thin ...

While phakic IOLs have traditionally been used to correct higher levels of myopia, Loh discussed data from 200 eyes with low to moderate myopia that achieved positive outcomes with the EVO ICL.

STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses ...

Please provide your email address to receive an email when new articles are posted on . KOLOA, Hawaii — In this Healio Video Perspective from Hawaiian Eye 2025, Neda Nikpoor, MD, of Jenkins Eye ...

This represents the company’s highest quarterly ICL sales in the U.S. since the company obtained U.S. FDA approval for the EVO ICL in March 2022. “STAAR is off to a solid start in 2024 as ...

Staar Surgical's 10% rise in net sales to $88.6 million dominated the third quarter's highlight reel, as strong traction in the EVO lens product line drove ICL sales. This growth was attributed to ...

LAKE FOREST, Calif., February 11, 2025--STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, ...

LAKE FOREST, Calif., February 11, 2025--STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision ...

STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced a leadership ...